Brenus Pharma
Manufacturing · France · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Parc Technologique Lavaur-la-béchade, Is...Website
www.brenus-pharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Brenus Pharma
Brenus Pharma specializes in developing first-in-class immunotherapies aimed at enhancing the immune response against tumors, particularly focusing on solid tumors. Their proprietary Stimulated Tumor Ghost Cells (SGC) technology addresses the limitations of traditional immunotherapies by mimicking tumor heterogeneity and improving patient access to innovative treatments. The company targets a wide range of patients suffering from various cancers, including colorectal and ovarian cancers, with a scalable and cost-efficient manufacturing process. Backed by significant funding and a team of experts, Brenus Pharma is committed to advancing cancer treatment through precision medicine and innovative therapeutic solutions.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Brenus Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Brenus Pharma launches new products
Brenus Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Brenus Pharma is spiking on competitors!
Funding: Get notified immidiatlly once Brenus Pharma has new funding data
Earning: See what the market has to say on Brenus Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Brenus Pharma has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Brenus Pharma
Click to see if Brenus Pharma had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Brenus Pharma as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Brenus Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Brenus Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Brenus Pharma.
Brenus Pharma financials insights
Gather financial insights about Brenus Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$25M
Brenus Pharma Tech Stack
A closer look at the technologies used by Brenus Pharma
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Funding
Funding
Event
Brenus Pharma News & Media
Brenus Pharma Raises $25 Million to Accelerate Clinical Trials of Its Precision Cancer Vaccines.
LYON, France--(BUSINESS WIRE)--Brenus Pharma, a biotech company specializing in the development of cancer vaccines, announces the completion of a $25 million Series A financing round. The round is led by Angelor, an investment fund bringing together a cluster of investors from the Auvergne-Rhône-Alpes (AURA) region, including UI Investissement for the Fonds régional Avenir industrie Auvergne-Rhône-Alpes, Crédit Agricole Centre-France and Crédit Agricole Centre-Est, with 2 family offices. BelgiaBrenus Pharma Wins French Tech Saint-Etienne Lyon's BIG Start-up of the Year Award
LYON, France--(BUSINESS WIRE)-- #BIGUP--During its annual event "BIG UP", French Tech Saint-Etienne Lyon awarded the BIG Start-up of the Year trophy, honoring a start-up that exemplifies the region's innovation and richness. French Tech Saint-Etienne Lyon, a non-profit association established in 2015, promotes the creation, growth, and internationalization of innovative companies in Lyon and Saint-Étienne. Designated as one of the 17 French Tech Capitals by the French government until 2026, it fBrenus Pharma graduates from the Creative Destruction Lab’s 2023/2024 Global Cancer Stream, in partnership with North American Universities.
LYON, France--(BUSINESS WIRE)-- #BiotechInnovation--A year ago, Brenus was selected to participate in CDL Cancer, a global mentorship program for massively scalable, science-based and innovative companies accelerating cancer treatment. Thanks to its pioneering STC platform, dedicated to developing a new generation of therapeutic cancer vaccines, Brenus stood out during a scientific evaluation with Dr. John Bell (Principal Senior Scientist at Ottawa Hospital Cancer Research Institute & ProfessorASCO 2024: Brenus Pharma Presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC
LYON, France--(BUSINESS WIRE)-- #ASCO2024--Brenus Pharma, French biotech developing its proprietary discovery platform: “Stimulated-Tumor-Cell” (STC), has presented the study design of “BreAK-CRC” First-in-human of STC-1010, Brenus’ lead candidate, during ASCO annual meeting (31st May – 4th June 2024) - Trials in Progress poster session, in Chicago. Poster here. | Benoit You et al. Journal of Clinical Oncology 42, TPS3635-TPS3635(2024). DOI:10.1200/JCO.2024.42.16_suppl.TPS3635 Authors informatio
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Brenus Pharma
Sign Up For FreeTo access detailed company insights
Brenus Pharma specializes in developing first-in-class immunotherapies aimed at enhancing the immune response against tumors, particularly focusing on solid tumors. Their proprietary Stimulated Tumor Ghost Cells (SGC) technology addresses the limitations of traditional immunotherapies by mimicking tumor heterogeneity and improving patient access to... Read More
